On June 23, Moderna rose 5.45% in regular trading, trading at $63.015/share, with turnover of $160 million. The rebound followed a sharp decline of over 5% in the prior session triggered by short-term profit-taking pressure.

Fundamentally, the stock continues to be supported by a significant regulatory milestone. The company's mRNA influenza vaccine mFlusiva recently received a unanimous 9-0 recommendation for approval from the FDA's Vaccines and Related Biological Products Advisory Committee for adults aged 50 and older. Clinical data demonstrated the vaccine can elicit a strong immune response in the target population. If approved, mFlusiva would become the first mRNA-based seasonal influenza vaccine in the United States. The FDA's final approval decision is expected in early August.

Additionally, Moderna's shares had surged approximately 39% over six trading sessions prior to the previous session's pullback, driven by the FDA advisory committee endorsement, positive vaccine efficacy data, and plans for production capacity expansion in Germany. The prior selloff was further pressured by Leerink Partners maintaining an underperform rating despite raising its target price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)